Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of October 2016. The registrant is a foreign private issuer based in Mechelen, Belgium, filing under Rule 13a-16 of the Securities Exchange Act of 1934. The report primarily serves to incorporate by reference a press release issued on October 12, 2016 (Exhibit 99.1).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing referencing an external press release rather than a financial statement.
Material Changes
No material financial changes or comparative period data are disclosed within the text of this Form 6-K. The filing indicates the issuance of a press release but does not summarize its content.
Guidance, Outlook, and Risks
The filing does not contain management commentary, guidance, outlook, or specific risk factors. It notes that the information in the attached press release is incorporated by reference into the Company's Registration Statements on Forms F-3 and S-8.
Investor Verification Checklist
- Verify the content of the press release dated October 12, 2016 (Exhibit 99.1), as the filing itself contains no operational details.
- Confirm the registrant name is Galapagos NV, noting a discrepancy with the provided metadata company name.
- Review the referenced Registration Statements (File Nos. 333-211765, 333-204567, 333-208697, and 333-211834) for full disclosure of the press release content.